Press Release

CSRXP: FINALIZED CMS COVERAGE DECISION FOR ADUHELM PROTECTS SENIORS AND TAXPAYERS FROM BIG PHARMA PRICE-GOUGING

Apr 8, 2022

Decision Appropriately Balances Access to Treatment with the Need for More Read More

CSRXP STATEMENT ON CONFIRMATION OF DR. ROBERT CALIFF AS COMMISSIONER OF U.S. FOOD AND DRUG ADMINISTRATION

Feb 15, 2022

FDA Can Play a Critical Role in Holding Big Pharma Accountable and Promoting Read More

CSRXP POLL: VOTERS SEE THROUGH BIG PHARMA’S BLAME GAME, WANT WASHINGTON TO LOWER DRUG PRICES & HOLD DRUG COMPANIES ACCOUNTABLE

Feb 7, 2022

Broad Majorities of Americans Blame Pharmaceutical Industry for Out-of-Control Read More

CSRXP: BIG PHARMA’S BUSINESS-AS-USUAL APPROACH TO JANUARY PRICE HIKES UNDERSCORES URGENCY FOR RX SOLUTIONS

Feb 2, 2022

Drug Companies Increased Prices on 785 Brand Name Products in First Month of Read More

CSRXP STATEMENT AHEAD OF COMMITTEE VOTE FOR DR. ROBERT CALIFF TO LEAD U.S. FOOD AND DRUG ADMINISTRATION

Jan 12, 2022

Next FDA Commissioner Must Promote Competition, Transparency And Value In The Read More

HAPPY NEW YEAR: BIG PHARMA HIKES PRICES ON MORE THAN 400 BRAND NAME DRUGS TO RING IN 2022

Jan 3, 2022

Fourth Major Round Of Pandemic Price Hikes Highlight Urgency for Policymakers Read More

CSRXP: LANDMARK OVERSIGHT REPORT DEBUNKS BIG PHARMA’S FALSE RHETORIC, ADDS TO MOMENTUM TO LOWER RX PRICES

Dec 10, 2021

U.S. House Oversight & Reform Committee Report Finds Big Pharma’s Read More

CSRXP: BIG PHARMA’S EGREGIOUS PRICING OF UNPROVEN ALZHEIMER’S TREATMENT DRIVES HIGHER PREMIUMS FOR SENIORS

Nov 12, 2021

Biogen’s Staggering $56,000 Price Tag for Treatment With No Proven Clinical Read More

CSRXP APPLAUDS INCLUSION OF PRESCRIPTION DRUG PRICING SOLUTIONS IN LATEST FRAMEWORK

Nov 2, 2021

Congress Should Reject Pharma-backed Proposals That Would Hike Health Care Read More

CSRXP: WHITE HOUSE FRAMEWORK FAILS ON PROMISE TO LOWER DRUG PRICES

Oct 28, 2021

Framework Fails to Hold Big Pharma Accountable and Lower Drug Prices for the Read More

CSRXP WELCOMES FDA APPROVAL OF FIRST INTERCHANGEABLE BIOSIMILAR FOR HUMIRA AS POSITIVE FIRST STEP

Oct 20, 2021

U.S. Food & Drug Administration Approval of Cyltezo Marks Second Read More